140 related articles for article (PubMed ID: 16051335)
1. Erythropoietin receptor function and expression in epithelial ovarian carcinoma.
McBroom JW; Acs G; Rose GS; Krivak TC; Mohyeldin A; Verma A
Gynecol Oncol; 2005 Dec; 99(3):571-7. PubMed ID: 16051335
[TBL] [Abstract][Full Text] [Related]
2. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.
Kim TJ; Rho SB; Choi YL; Choi CH; Lee JW; Bae DS; Ahn G; Lee JH; Kim BG
Hum Pathol; 2006 Jul; 37(7):906-13. PubMed ID: 16784992
[TBL] [Abstract][Full Text] [Related]
3. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
4. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
Wang P; Wu X; Chen W; Liu J; Wang X
Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells.
Feldman L; Wang Y; Rhim JS; Bhattacharya N; Loda M; Sytkowski AJ
Prostate; 2006 Feb; 66(2):135-45. PubMed ID: 16161153
[TBL] [Abstract][Full Text] [Related]
6. Expression of erythropoietin and its receptor in neuroblastomas.
Sartelet H; Fabre M; Castaing M; Bosq J; Racu I; Lagonotte E; Scott V; Lecluse Y; Barette S; Michiels S; Vassal G
Cancer; 2007 Sep; 110(5):1096-106. PubMed ID: 17647284
[TBL] [Abstract][Full Text] [Related]
7. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
[TBL] [Abstract][Full Text] [Related]
8. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
9. Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors.
Rodabaugh KJ; Mhawech-Fauceglia P; Groth J; Lele S; Sood AK
Int J Gynecol Pathol; 2007 Jan; 26(1):10-5. PubMed ID: 17197890
[TBL] [Abstract][Full Text] [Related]
10. [Expressions of VEGF/VEGFRs and activation of STATs in ovarian carcinoma].
Chen BY; Ye DF; Xie X; Chen HZ; Lü WG
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):33-7. PubMed ID: 15771796
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
[TBL] [Abstract][Full Text] [Related]
12. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Boivin M; Lane D; Piché A; Rancourt C
Gynecol Oncol; 2009 Dec; 115(3):407-13. PubMed ID: 19747716
[TBL] [Abstract][Full Text] [Related]
13. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
14. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
Hu YQ; Liu YJ
Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
[TBL] [Abstract][Full Text] [Related]
15. Significance of Fas receptor protein expression in epithelial ovarian cancer.
Reed J; Hakam A; Nicosia SV; Coppola D
Hum Pathol; 2005 Sep; 36(9):971-6. PubMed ID: 16153459
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of laminin-5 in serous adenocarcinomas of the ovary.
Kohlberger P; Muller-Klingspor V; Heinzl H; Obermair A; Breitenecker G; Leodolter S
Anticancer Res; 2002; 22(6B):3541-4. PubMed ID: 12552953
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin and erythropoietin receptor expression in human cancer.
Acs G; Acs P; Beckwith SM; Pitts RL; Clements E; Wong K; Verma A
Cancer Res; 2001 May; 61(9):3561-5. PubMed ID: 11325818
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
19. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
20. Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells.
Ota T; Klausen C; Salamanca MC; Woo HL; Leung PC; Auersperg N
Differentiation; 2009 Feb; 77(2):162-71. PubMed ID: 19281776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]